SANN — Santhera Pharmaceuticals Holding AG Balance Sheet
0.000.00%
Last trade - 00:00- CH₣163.59m
- CH₣163.29m
- CH₣39.12m
Annual balance sheet for Santhera Pharmaceuticals Holding AG, fiscal year end - December 31st, CHF millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | C2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Equivalents | |||||
| Cash and Short Term Investments | 12.4 | 21.2 | 1.35 | 30.4 | 40.9 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 4.49 | 1.94 | 1.09 | 2.15 | 13.9 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 17.7 | 24.6 | 3.06 | 34.7 | 75.8 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 1.9 | 1.32 | 1.01 | 0.582 | 2.57 |
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Other Long Term Assets | |||||
| Total Assets | 88.7 | 91.1 | 63.7 | 110 | 152 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 29.1 | 32.8 | 49.4 | 45.8 | 46.1 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Funded Status | |||||
| Total Liabilities | 95 | 89.8 | 107 | 49.7 | 125 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Treasury Stock | |||||
| Other Equity | |||||
| Total Equity | -6.35 | 1.33 | -43.7 | 59.9 | 27.7 |
| Total Liabilities & Shareholders' Equity | 88.7 | 91.1 | 63.7 | 110 | 152 |
| Total Common Shares Outstanding |